Arcadia Biosciences Inc. (RKDA)
Arcadia Biosciences Statistics
Share Statistics
Arcadia Biosciences has 1.37M shares outstanding. The number of shares has increased by 0.31% in one year.
| Shares Outstanding | 1.37M |
| Shares Change (YoY) | 0.31% |
| Shares Change (QoQ) | 0.15% |
| Owned by Institutions (%) | 99.99% |
| Shares Floating | 1.36M |
| Failed to Deliver (FTD) Shares | 24 |
| FTD / Avg. Volume | 0.27% |
Short Selling Information
The latest short interest is 13.62K, so 1% of the outstanding shares have been sold short.
| Short Interest | 13.62K |
| Short % of Shares Out | 1% |
| Short % of Float | 1.01% |
| Short Ratio (days to cover) | 0.33 |
Valuation Ratios
The PE ratio is -1.15 and the forward PE ratio is -4.02. Arcadia Biosciences's PEG ratio is 0.02.
| PE Ratio | -1.15 |
| Forward PE | -4.02 |
| PS Ratio | 1.6 |
| Forward PS | 0.5 |
| PB Ratio | 1.3 |
| P/FCF Ratio | -0.84 |
| PEG Ratio | 0.02 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Arcadia Biosciences.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 3.61, with a Debt / Equity ratio of 0.02.
| Current Ratio | 3.61 |
| Quick Ratio | 3.25 |
| Debt / Equity | 0.02 |
| Debt / EBITDA | -0.02 |
| Debt / FCF | -0.02 |
| Interest Coverage | 0 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $560.56K |
| Profits Per Employee | $-782K |
| Employee Count | 9 |
| Asset Turnover | 0.37 |
| Inventory Turnover | 3.28 |
Taxes
| Income Tax | 8K |
| Effective Tax Rate | -0.19% |
Stock Price Statistics
The stock price has increased by 31.53% in the last 52 weeks. The beta is 0.86, so Arcadia Biosciences's price volatility has been higher than the market average.
| Beta | 0.86 |
| 52-Week Price Change | 31.53% |
| 50-Day Moving Average | 4.03 |
| 200-Day Moving Average | 3.72 |
| Relative Strength Index (RSI) | 27.46 |
| Average Volume (20 Days) | 8.86K |
Income Statement
In the last 12 months, Arcadia Biosciences had revenue of 5.04M and earned -7.04M in profits. Earnings per share was -5.16.
| Revenue | 5.04M |
| Gross Profit | 2.08M |
| Operating Income | -3.65M |
| Net Income | -7.04M |
| EBITDA | -7.5M |
| EBIT | -7.61M |
| Earnings Per Share (EPS) | -5.16 |
Balance Sheet
The company has 4.24M in cash and 155K in debt, giving a net cash position of 4.09M.
| Cash & Cash Equivalents | 4.24M |
| Total Debt | 155K |
| Net Cash | 4.09M |
| Retained Earnings | -278.88M |
| Total Assets | 13.52M |
| Working Capital | 6.68M |
Cash Flow
In the last 12 months, operating cash flow was -9.63M and capital expenditures -16K, giving a free cash flow of -9.64M.
| Operating Cash Flow | -9.63M |
| Capital Expenditures | -16K |
| Free Cash Flow | -9.64M |
| FCF Per Share | -7.07 |
Margins
Gross margin is 41.27%, with operating and profit margins of -72.31% and -139.5%.
| Gross Margin | 41.27% |
| Operating Margin | -72.31% |
| Pretax Margin | -85.41% |
| Profit Margin | -139.5% |
| EBITDA Margin | -148.64% |
| EBIT Margin | -72.31% |
| FCF Margin | -191.14% |
Dividends & Yields
RKDA does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Analyst Forecast
The average price target for RKDA is $6, which is 124.7% higher than the current price. The consensus rating is "Buy".
| Price Target | $6 |
| Price Target Difference | 124.7% |
| Analyst Consensus | Buy |
| Analyst Count | 1 |
Stock Splits
The last stock split was on Mar 1, 2023. It was a backward split with a ratio of 1:40.
| Last Split Date | Mar 1, 2023 |
| Split Type | backward |
| Split Ratio | 1:40 |
Scores
| Altman Z-Score | -29.83 |
| Piotroski F-Score | 1 |